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Background: Cystic fibrosis (CF) is one of the most common hereditary disorders among Caucasians. The most common muta-
tions of the cystic fibrosis transmembrane conductance regulator (CFTR) gene have been well established among Caucasian popu-
lations. In Koreans, however, there are very few cases of genetically confirmed CF thus far, and the spectrum of mutations seems 
quite different from that observed in Caucasians. 
Methods: In the present study, we describe the cases of 2 Korean CF patients, present sequencing results identifying mutations in 
their CFTR gene, and summarize the results of CFTR mutational spectrum from previously reported Korean CF patients. The muta-
tions described were identified by performing direct sequencing analysis of the complete coding regions and flanking intronic se-
quences of the CFTR gene, followed by multiplex ligation-dependent probe amplification (MLPA) analysis in order to detect gene 
deletions or duplications that could not be identified by a direct sequencing method.
Results: Three CFTR mutations were identified in the 2 patients, including p.Q98R, c.2052delA, and c.579+5G>A. In an analysis of 9 
Korean CF patients that included the 2 patients presented in this study, p.Q98R mutation was the only recurrently observed muta-
tion with a frequency of 18.8% (3/16 alleles). Furthermore, only one of the mutations (c.3272-26A>G) was found among the 32 
common mutations in the screening panel for Caucasians from the Cystic Fibrosis Mutation Database.
Conclusions: Sequencing of the entire CFTR gene followed by MLPA analysis, rather than using the targeted sequencing-based 
screening panel for mutations commonly found in Caucasian populations, is recommended for genetic analysis of Korean CF pa-
tients.
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INTRODUCTION
Cystic Fibrosis (CF) is an autosomal recessive disease of 
exocrine tissues; the disease is characterized by the abnor-
mal transport of ions and fluid across epithelial cell mem-
branes. Mutations in the cystic fibrosis transmembrane con-
ductance regulator (CFTR) gene are responsible for both 
classical and atypical presentations of the disease, including 
pulmonary disease, pancreatic insufficiency, malabsorption, 
meconium ileus, failure to thrive, infertility, and elevated 
concentrations of chloride in sweat [1]. A diagnosis of CF is 
based upon several findings, including the presence of typi-
cal clinical features, history of CF in a sibling, positive sweat 
test, identification of CFTR mutations in both alleles, and an 
abnormal nasal potential difference measurement [2].220     www.kjlm.org
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The CFTR gene spans an approximately 240-kb region on 
chromosome 7q31.3 and consists of 27 exons [3-5]. It en-
codes a membrane protein of 1,480 amino acids that func-
tions as a cAMP-regulated chloride channel in exocrine epi-
thelia [6]. CF is a very common hereditary disease in Cauca-
sian populations with incidences ranging from 1 in 2,500-
3,500 in the U.S. [7, 8] and approximately 1 in 1,000-3,000 
newborns in Europe [9]. However, CF is quite rare in Asian 
populations, and an epidemiological study in a Japanese pop-
ulation found the incidence of CF to be about 1 in 350,000 
[10, 11]. CF is also extremely rare in the Korean population 
and only 10 patients with CF have been reported thus far, of 
which 7 cases were confirmed by genetic analysis [12-19].
There are currently over 1,700 mutations listed in the 
CFTR mutation database [20]. The most common mutation 
of the CFTR gene in Caucasian populations is a p.F508del, 
and this mutation is found in approximately 70% of Cauca-
sian CF patients [1], whereas the incidence of other muta-
tions remains about 2-3% per mutation [21]. Interestingly, 
the p.F508del is not a common mutation in Asian popula-
tions and has frequencies of 19-44% in Indians [22-25], 
17.3% in Pakistanis [26], and 18.1% in Iranians [27]. Fur-
ther, of the few reports of genomic DNA analysis of Japa-
nese patients with CF, there have been no cases where a 
p.F508del mutation was found [11].
Currently, not much data is available on the spectrum of 
mutations in Korean CF patients. Here, we describe the cases 
of 2 CF patients and have summarized the mutational spec-
trum of the CFTR gene from Korean CF patients in order to 
further characterize the specific mutational pattern of the 
CFTR gene in the Korean population.
MATERIALS AND METHODS
1. Patients
Patient 1 was a 22-yr-old woman who was admitted for 
antibiotic therapy of infection with nontuberculous myco-
bacteria (NTM). The patient had been treated for several 
episodes of chronic productive cough, sputum, and pneu-
monia, which necessitated frequent visits to the outpatient 
clinic. At the age of 17, she was admitted to a civil hospital 
for the treatment of pulmonary tuberculosis and had receiv-
ed antituberculosis drug therapy for 15 months. Her respira-
tory symptoms progressively worsened, and she was diag-
nosed with bronchiectasis and a NTM infection. She had an 
older brother with an unremarkable medical history. There 
was no evidence of exocrine pancreatic insufficiency or mal-
absorption. The sweat chloride concentration was measured 
by a quantitative pilocarpine iontophoresis sweat test, in ac-
cordance with the guidelines of the Clinical and Laboratory 
Standards Institute. The average sweat chloride concentra-
tion on both forearms was 81.2 mmol/L, which exceeded 
the upper limit of the reference range (<60 mmol/L).
Patient 2 was a 31-yr-old woman complaining of chronic 
productive cough, sputum, and recent hemoptysis without 
any gastrointestinal symptoms. The patient had been treated 
for these symptoms with antibiotics, but no improvement 
was noted. After a preliminary diagnosis of community-ac-
quired pneumonia, she was admitted for further work-up 
and treatment. During her infancy, she had pertussis. She 
had recurrently received antituberculosis treatment from 
the age 15, with repeated events of remission and relapse of 
pulmonary tuberculosis. No evidence of exocrine pancre-
atic insufficiency or malabsorption was found. The average 
sweat chloride concentration was elevated (112.4 mmol/L), 
which was highly suggestive of CF.
2. Mutation analysis
Informed consent was obtained from all parents and 
family members, and patient confidentiality was been 
maintained. Genomic DNA was isolated from peripheral 
blood leukocytes by using the Wizard Genomic DNA Puri-
fication Kit, according to the manufacturer’s instructions 
(Promega, Madison, WI, USA). The presence of mutations 
in all 27 exons and exon-intron boundaries of the CFTR 
gene was assessed by polymerase chain reaction (PCR) and 
direct sequencing using primer pairs designed by the au-
thors. PCR was performed using a thermal cycler (Model 
9600; Applied Biosystems, Foster City, CA, USA), and cycle 
sequencing was performed using the ABI Prism 3100 Ge-
netic Analyzer with the BigDye Terminator Cycle Sequenc-
ing Ready Reaction Kit (Applied Biosystems). Sequence 
variations were analyzed with reference to the wild-type se-
quence (GenBank Accession No. NM_00492.3) by using 
the Sequencher program (Gene Codes Corp., Ann Arbor, 
MI, USA).
When a large deletion mutation was thought to be present, 
multiplex ligation-dependent probe amplification (MLPA) 
analysis was performed using the SALSA P091-C1 CFTR 
test kit (MRC-Holland, Amsterdam, the Netherlands), ac-
cording to the manufacturer’s protocol [28]. The P091-C1 
CFTR probemix contains 5 control fragments and 43 differ-
ent probes with amplification products. Briefly, 100 ng of ge-
nomic DNA was denatured at 98˚C and hybridized with the 
CFTR-MLPA probe mix at 60˚C for 16 hr. Subsequently, the 
annealed probe was ligated to the Ligase-65 mix at 54˚C for 
15 min. The appropriate PCR primers, dNTPs, SALSA PCR 
buffer, and SALSA polymerase were added, and the subse-Jung H, et al.  •  CFTR Mutations in Korean Cystic Fibrosis Cases
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quent PCR reactions were performed. Each probe amplifica-
tion product, 1 µL in volume, was then mixed with 0.5 µL 
GeneScan
TM500 ROX
TM Size Standard (Applied Biosystems, 
Warrington, UK) and 8.5 µL HiDi Formamide (Applied Bio-
systems). Electrophoresis of the PCR products was per-
formed using the ABI 3130 Genetic Analyzer (Applied Bio-
systems, Foster, CA, USA), and the MLPA data were ana-
lyzed using GeneMarker 1.6 software (SoftGenetics, LLC., 
State College, PA, USA). A normal copy number is expected 
to generate a normalized signal value of 1.
3. Clinical findings and spectrum of mutations in Korean CF 
  patients
In order to study the spectrum of mutations in Korean 
CF patients, we reviewed the previously identified CF pa-
tients at our institution (N=4) [14, 15, 17, 18] and in the lit-
erature (N=3) [16, 19, 29] in addition to the cases analyzed 
in this report (N=2). Only genetically confirmed cases were 
included in this study. 
RESULTS
1. Genetic analysis of the 2 Korean patients
Two mutations in the CFTR gene were found in Patient 1: 
a heterozygous A to G transition in exon 4 [c.293A>G (p. 
Q98R)] and a heterozygous deletion of an A in exon 13 
[c.2052delA (p.L728NfsX38)]. A family study showed that 
her mother and older brother both also possessed the c. 
2052delA mutation. No targeted genetic testing was done 
on her father. Our search of the Cystic Fibrosis Mutation 
Database [20] showed that the p.Q98R and c.2052delA mu-
tations have also been reported in CF patients from France.
In Patient 2, a heterozygous splicing mutation in intron 4 
(c.579+5G>A) was identified, but we were unable to detect 
the mutation that must presumably have been present on 
the opposite allele. No further genetic study was done on 
her family members. The CFTR mutations from the families 
of the 2 patients are summarized in the pedigree (Fig. 1).
2. Clinical findings in 9 Korean CF patients
The average ages of 9 patients (7 female and 2 male pa-
tients) at diagnosis and at presentation of symptoms were 
13 and 2.8 yr, respectively. Five patients were diagnosed 
with CF under the age of 16 and the other 4 patients were 
clinically diagnosed with CF during adulthood (Table 1). 
None of the patients had a history of sibling death due to 
respiratory or gastrointestinal problems or any symptoms 
related to CF in family members.
The respiratory symptoms were clinically documented in 
the CF patients as follows: chronic cough (N=7; 78%), spu-
tum (N=4; 44%), sinusitis (N=4; 44%), recurrent or persis-
Table 1. Demographics and clinical findings of Korean CF patients
Case
No. Sex Age 
at Dx
Age at
1st Sx Clinical symptoms Sputum culture Sweat Cl
- concentration 
(mmol/L)
1 F 22 yr 1 yr Chronic cough, Sputum, Pneumonia  M. abscessus 81.2
2 F 31 yr 15 yr Chronic cough, Sputum, Sinusitis, Pneumonia P. aeruginosa, Aspergillosis 112.4
3 M 21 yr 2 yr Chronic cough, Pansinusitis S. aureus 63.0
4 F 3 yr 2 days Meconium ileus ND ND
5 F 2 yr 2 mo Chronic cough, Steatorrhea, Failure to thrive, Pneumonia MRSA 102.0
6 F 18 yr 13 yr Chronic cough, Sinusitis, Pneumonia S. aureus, P. aeruginosa 102.5
7 F 15 yr 1 mo Chronic cough, Sputum, Sinusitis, Pneumonia, Clubbed fingers, Diarrhea, Abdominal pain MRSA, P. aeruginosa 102.4
8 M 4 mo 1 day Meconium ileus, Fatty liver S. aureus, S. maltophilia ND
9 F 5 yr 4 yr Chronic cough, Sputum, Pneumonia, Diarrhea, Fatty liver, Atrophy of pancreas P. aeruginosa 88.7
Abbreviations: Dx, Diagnosis; Sx, Symptom; ND, not done; S. aureus, Staphylococcus aureus; MRSA, Methicillin-resistant S. aureus; P. aeruginosa, Pseudomonas aeruginosa; M. absces-
sus, Mycobacterium abscessus; S. maltophilia, Stenotrophomonas maltophilia.
Fig. 1. Pedigree of families of 2 Korean CF patients. The probands are indi-
cated by black solid circles with an arrow, and the carriers are indicated by a 
central dot. (A) Family of Patient 1. (B) Family of Patient 2.
Abbreviation: ND, not done.
II:1
c.[579+5G>A]+[?]
II:1
c.[293A>G]+[2052delA]
II:2
c.2052delA
I:2
c.2052delA
I:1
ND
I:1
ND
I:2
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tent pneumonia (N=7; 78%), and bronchiectasis (N=5; 
56%). Infections related with CF were pulmonary tuberculo-
sis (N=5; 56%), aspergillosis (N=1; 11%), and infections 
with NTM (N=1; 11%), Staphylococcus aureus (N=5; 56%), 
Pseudomonas aeruginosa (N=4; 44%), and Stenotroph-
omonas maltophilia (N=1; 11%). Most of the patients had 
experienced infections of S. aureus and P. aeruginosa, which 
are well-known clinical infections of CF, during the course 
of their disease progression. Other symptoms observed in 
the CF patients were a history of failure to thrive (N=1; 
11%), steatorrhea (N=3; 33%), clubbed fingers (N=1; 
11%), fatty liver (N=2; 22%), pancreatic atrophy (N=1, 
11%) and meconium ileus (N=2; 22%) (Table 1). 
All patients were diagnosed with CF on the basis of clas-
sical clinical phenotypes and high sweat chloride concen-
tration (>60 mEq/L). The median sweat chloride concen-
tration of 7 patients was 93.2 mmol/L, and all patients 
tested showed high sweat chloride concentration. In 2 neo-
nates, the sweat test could not be done because of their 
young age.
3. Spectrum of mutations in the 9 Korean CF patients
A total of 16 disease-causing mutations of the CFTR gene 
were identified in the 9 Korean CF patients (Table 2). All 
identified mutations were detected by PCR and direct se-
quencing with the exception of a large deletion in exon 14a, 
which was detected by MLPA. No p.F508del mutations, 
known to be the most common mutation among Cauca-
sians, were detected in the Korean patients of this study. 
The identified mutations included 3 missense mutations 
(p.Q98R, p.Q1352H, and p.L441P), 3 nonsense mutations 
(p.Q220X, p.Q1291X, and p.L88X), 1 duplication with fra-
meshift (c.3908dupA), 1 insertion with frameshift (c.2089-
2090insA), 4 splice site mutations (c.1766+2T>C, c.3272-
26A>G, c.579+5G>A, and IVS8-T5) and 2 deletion muta-
tions (c.2052delA and c.2623-?_2751+?del). 
The p.Q98R mutation was the only recurrently observed 
mutation, with a frequency of 18.8% (3/16 alleles). Muta-
tions on both alleles were identified in 7 out of 9 patients. 
All identified mutations of the CF patients examined were 
confirmed with targeted genetic tests in consenting family 
members. Eight out of 9 families were tested, and all parents 
of the patients, except in 1 family (case 9), were proven to 
be heterozygous carriers of the mutations with no pheno-
typic abnormalities (Table 2).
DISCUSSION
Accurate knowledge of CF mutations in specific popula-
tions provides information for CF prevention programs ap-
plicable via heterozygote screening and prenatal diagnosis 
[25]. The identification of mutations and their frequencies 
is thus critically important for designing gene probes for ef-
fective diagnosis of CF in a given population. Further, dif-
Table 2. Frequency of CFTR mutations in Korean CF patients
Case
No.
Amino acid
change Exon Nucleotide
number
Nucleotide
change
Type of
mutation
Method 
of detection
Familial targeted mutation study 
Ref
Father Mother Brother Sister
1 Q98R Exon 4 293 A>G Missense Sequencing ND − − NA This study
L728NfsX38 Exon 13 2,052 delA Frameshift Sequencing ND + + NA
2 IVS 4 579+5 G>A Splicing Sequencing ND ND NA NA This study
3 Q98R Exon 4 293 A>G Missense Sequencing + − + − [15]
Q220X Exon 6a 658 C>T Nonsense Sequencing − + − −
4 Q98R Exon 4 293 A>G Missense Sequencing + − NA NA [16]
Q1352H Exon 24 4,056 G>C Missense Sequencing − + NA NA
5 IVS 12 1,766+2 T>C  Splicing Sequencing + − NA NA [18]
N1303KfsX6 Exon 21 3,908 dupA Frameshift Sequencing − + NA NA
6 IVS 17a 3,272-26 A>G Splicing Sequencing  MLPA ND ND NA NA [17]
Exon14a 2,623-2,751+? del Deletion + − NA NA
7 Q1291X Exon 20 4,003 C>T Nonsense Sequencing + − + NA [14]
IVS8 T5 Splicing Sequencing − + − NA
8 L88X Exon 3 263 T>G Nonsense Sequencing + − NA NA [29]
R697KfsX33 Exon 13 2,089-2,090 insA Insertion Sequencing − + NA NA
9 L441P Exon 9 1,454 T>C Missense Sequencing & DGGE ND − ND NA [19]
Abbreviations: IVS, intervening sequence; MLPA, multiplex ligation-dependent probe amplification; ND, not done; NA, not applicable; DGGE, denaturing gradient gel electrophoresis.Jung H, et al.  •  CFTR Mutations in Korean Cystic Fibrosis Cases
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ferent mutations are associated with varying severity of dis-
ease with implications on management and prognosis [26]. 
However, limited data are available on the spectrum of mu-
tations in Korean CF patients. Therefore, this study was 
planned to characterize the mutational spectrum of the 
CFTR gene in Korean CF patients. 
Currently over 1,700 mutations are listed in the Cystic Fi-
brosis Mutation Database [20]. However, only a few muta-
tions have been reported in the Korean population. No mu-
tation, except p.Q98R, has repeatedly been observed in Ko-
rean CF patients in this study. Furthermore, only one of the 
32 common mutations found in the screening panel for 
Caucasians was identified in this Korean population, name-
ly, the c.3272-26A>G mutation [20]. 
A noteworthy characteristic of the mutational spectrum 
of the Korean CFTR gene is the absence of mutations that 
are common in the European and American populations. 
This highly heterogeneous mutational spectrum suggests 
that a screening set of common CFTR mutations is of little 
use for the Korean population. Rather, sequencing of entire 
gene and complementary MLPA might be a more feasible 
way to accurately confirm a diagnosis of CF. Sequencing 
analysis detects more than 98% of CFTR mutations [30], 
and MLPA can detect deletions not identified by sequence 
analysis. However, the mutation detection rate of MLPA is 
not currently known.
Although CF tends to be detected early in life, diagnosis 
of CF is being made in adults with increased frequency [31, 
32]. Patients who are diagnosed with CF when they are 
adults normally present with chronic respiratory problems. 
As a group, they have a milder variant of lung disease, a 
lesser degree of Pseudomonas infection, and are more likely 
to be pancreatic-sufficient than patients in whom CF is di-
agnosed at earlier ages [31, 32]. In the Korean CF patients 
in our study, half were diagnosed when they were adults 
and presented with chronic respiratory problems such as 
chronic productive cough, sputum, and recurrent pneumo-
nia and presented with bronchiectasis in a more advanced 
disease. Pseudomonal and staphylococcal infections were 
observed in 4 (4/9, 44%) and 5 (5/9, 56%) patients, respec-
tively. Further, the lower number of reported CF diagnoses 
in the Korean population may suggest that CF is under-di-
agnosed in Korea.
In Patients 2 and 9, one of the causative mutations was 
not identified either by direct sequencing or by MLPA anal-
ysis. The CFTR mutation detection rate varies depending 
on the test method and ethnic background. In some symp-
tomatic individuals, only one or neither disease-causing 
mutation is detectable; in some carriers, the disease-causing 
mutation is not detectable. This may indicate a molecular 
defect in a non-coding or promoter region or a deep intron-
ic region of the gene, which may have led to a truncated or 
abnormal protein as a result of deregulated promoter sig-
nals or abnormal splicing. Moreover, the splicing mutation 
observed in Patient 2 (c.579+5G>A) has also been reported 
in CF patients from Italy, according to the Cystic Fibrosis 
Mutation Database [20].
Physicians who are not familiar with the spectrum of CF’s 
phenotypic manifestations may not consider CF when per-
forming their differential diagnoses, thus delaying accurate 
diagnosis [15]. As a result, CF patients are frequently misdi-
agnosed and treated for tuberculosis and other diseases. 
Five CF patients (56%) from our study had previously been 
diagnosed and treated for pulmonary tuberculosis. Althou-
gh sweat chloride analysis is considered to be the gold stan-
dard for screening CF, the test is difficult to perform be-
cause of insufficient standardization of the procedure and 
issues with reimbursement in Korea. 
Whilst the frequency of the p.F508del mutation is 87% in 
Northern Europe, it is only 28% in Asia and the Middle 
East, with a combined worldwide frequency of 66% (The 
Cystic Fibrosis Mutation Database 2010; The CF Genetic 
Analysis Consortium [1994]) [26]. No p.F508del mutations 
were detected in the Korean patients of this study. CF muta-
tion frequencies vary widely among different populations, 
and haplotype heterogeneity has been found to be greater 
in populations with lower p.F508del frequencies [33]. The 
heterogeneous mutational spectrum observed in this study 
also confirms these previous findings of high haplotype 
heterogeneity with lower p.F508del frequencies. Therefore, 
screening for CF with p.F508del mutation analysis alone is 
not recommended in Korean patients.
In summary, we report the cases of 2 Korean CF patients 
with 3 known CFTR mutations (p.Q98R, c.2052delA, and 
c.579+5G>A), and these mutations have been submitted to 
the Cystic Fibrosis Mutation Database [20]. The heteroge-
neous mutational spectrum of the CFTR gene in this Ko-
rean population suggests that full sequencing, covering a 
broader range of the CFTR genome, is a better diagnostic 
method for Korean CF patients. In addition, MLPA analysis 
for the detection of large deletions or duplications can be 
used as a complementary tool to the direct sequencing 
method. Even though a large amount of research is required 
before all the CFTR mutations in the Korean population are 
characterized by whole gene sequencing, future genomics 
tools will allow us to develop more advanced diagnostic era 
for cystic fibrosis. This can be made possible by standard-
ized molecular tests utilizing whole genome sequencing 224     www.kjlm.org
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and full gene sequencing accompanied by MLPA.
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